Utah Medical Products (UTMD) Competitors

Utah Medical Products logo
$66.47 +1.26 (+1.93%)
Closing price 04:00 PM Eastern
Extended Trading
$66.48 +0.01 (+0.02%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UTMD vs. CERS, OSUR, ANIK, WST, and COO

Should you buy Utah Medical Products stock or one of its competitors? MarketBeat compares Utah Medical Products with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Utah Medical Products include Cerus (CERS), OraSure Technologies (OSUR), Anika Therapeutics (ANIK), West Pharmaceutical Services (WST), and Cooper Companies (COO). These companies are all part of the "health care supplies" industry.

How does Utah Medical Products compare to Cerus?

Utah Medical Products (NASDAQ:UTMD) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

69.6% of Utah Medical Products shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 8.0% of Utah Medical Products shares are owned by insiders. Comparatively, 5.6% of Cerus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Utah Medical Products has a net margin of 28.90% compared to Cerus' net margin of -4.41%. Utah Medical Products' return on equity of 9.13% beat Cerus' return on equity.

Company Net Margins Return on Equity Return on Assets
Utah Medical Products28.90% 9.13% 8.86%
Cerus -4.41%-15.18%-4.38%

Cerus has a consensus target price of $4.00, indicating a potential upside of 51.52%. Given Cerus' stronger consensus rating and higher possible upside, analysts plainly believe Cerus is more favorable than Utah Medical Products.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Utah Medical Products
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cerus
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Utah Medical Products has higher earnings, but lower revenue than Cerus. Cerus is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Utah Medical Products$38.52M5.49$11.29M$3.3819.67
Cerus$206.13M2.57-$15.63M-$0.05N/A

In the previous week, Utah Medical Products and Utah Medical Products both had 1 articles in the media. Cerus' average media sentiment score of 0.08 beat Utah Medical Products' score of 0.00 indicating that Cerus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Utah Medical Products
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cerus
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Utah Medical Products has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Cerus has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Summary

Utah Medical Products beats Cerus on 8 of the 15 factors compared between the two stocks.

How does Utah Medical Products compare to OraSure Technologies?

OraSure Technologies (NASDAQ:OSUR) and Utah Medical Products (NASDAQ:UTMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Utah Medical Products has lower revenue, but higher earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OraSure Technologies$115.02M2.60-$68.73M-$1.04N/A
Utah Medical Products$38.52M5.49$11.29M$3.3819.67

93.5% of OraSure Technologies shares are owned by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are owned by institutional investors. 4.7% of OraSure Technologies shares are owned by insiders. Comparatively, 8.0% of Utah Medical Products shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Utah Medical Products has a net margin of 28.90% compared to OraSure Technologies' net margin of -66.42%. Utah Medical Products' return on equity of 9.13% beat OraSure Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
OraSure Technologies-66.42% -18.57% -15.71%
Utah Medical Products 28.90%9.13%8.86%

OraSure Technologies has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Utah Medical Products has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

OraSure Technologies currently has a consensus price target of $3.00, indicating a potential downside of 30.88%. Given OraSure Technologies' higher probable upside, equities analysts plainly believe OraSure Technologies is more favorable than Utah Medical Products.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OraSure Technologies
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Utah Medical Products
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Utah Medical Products had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 1 mentions for Utah Medical Products and 0 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 0.00 equaled Utah Medical Products'average media sentiment score.

Company Overall Sentiment
OraSure Technologies Neutral
Utah Medical Products Neutral

Summary

Utah Medical Products beats OraSure Technologies on 10 of the 14 factors compared between the two stocks.

How does Utah Medical Products compare to Anika Therapeutics?

Anika Therapeutics (NASDAQ:ANIK) and Utah Medical Products (NASDAQ:UTMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Anika Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Utah Medical Products has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by insiders. Comparatively, 8.0% of Utah Medical Products shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Utah Medical Products has lower revenue, but higher earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anika Therapeutics$112.82M1.74-$10.88M-$0.79N/A
Utah Medical Products$38.52M5.49$11.29M$3.3819.67

Utah Medical Products has a net margin of 28.90% compared to Anika Therapeutics' net margin of -9.52%. Utah Medical Products' return on equity of 9.13% beat Anika Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Anika Therapeutics-9.52% -5.90% -4.52%
Utah Medical Products 28.90%9.13%8.86%

Anika Therapeutics currently has a consensus target price of $17.00, indicating a potential upside of 15.41%. Given Anika Therapeutics' higher probable upside, analysts clearly believe Anika Therapeutics is more favorable than Utah Medical Products.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anika Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Utah Medical Products
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Anika Therapeutics had 1 more articles in the media than Utah Medical Products. MarketBeat recorded 2 mentions for Anika Therapeutics and 1 mentions for Utah Medical Products. Anika Therapeutics' average media sentiment score of 0.40 beat Utah Medical Products' score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anika Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Utah Medical Products
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Utah Medical Products beats Anika Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Utah Medical Products compare to West Pharmaceutical Services?

Utah Medical Products (NASDAQ:UTMD) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Utah Medical Products has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

West Pharmaceutical Services has higher revenue and earnings than Utah Medical Products. Utah Medical Products is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Utah Medical Products$38.52M5.49$11.29M$3.3819.67
West Pharmaceutical Services$3.07B7.85$493.70M$7.4845.66

West Pharmaceutical Services has a consensus price target of $340.09, indicating a potential downside of 0.42%. Given West Pharmaceutical Services' stronger consensus rating and higher possible upside, analysts clearly believe West Pharmaceutical Services is more favorable than Utah Medical Products.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Utah Medical Products
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
West Pharmaceutical Services
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00

Utah Medical Products pays an annual dividend of $1.24 per share and has a dividend yield of 1.9%. West Pharmaceutical Services pays an annual dividend of $0.88 per share and has a dividend yield of 0.3%. Utah Medical Products pays out 36.7% of its earnings in the form of a dividend. West Pharmaceutical Services pays out 11.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Utah Medical Products has raised its dividend for 3 consecutive years. Utah Medical Products is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

69.6% of Utah Medical Products shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 8.0% of Utah Medical Products shares are owned by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Utah Medical Products has a net margin of 28.90% compared to West Pharmaceutical Services' net margin of 16.85%. West Pharmaceutical Services' return on equity of 19.03% beat Utah Medical Products' return on equity.

Company Net Margins Return on Equity Return on Assets
Utah Medical Products28.90% 9.13% 8.86%
West Pharmaceutical Services 16.85%19.03%14.06%

In the previous week, West Pharmaceutical Services had 6 more articles in the media than Utah Medical Products. MarketBeat recorded 7 mentions for West Pharmaceutical Services and 1 mentions for Utah Medical Products. West Pharmaceutical Services' average media sentiment score of 0.94 beat Utah Medical Products' score of 0.00 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Utah Medical Products
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
West Pharmaceutical Services
4 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

West Pharmaceutical Services beats Utah Medical Products on 16 of the 20 factors compared between the two stocks.

How does Utah Medical Products compare to Cooper Companies?

Cooper Companies (NASDAQ:COO) and Utah Medical Products (NASDAQ:UTMD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Cooper Companies has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Utah Medical Products has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

Utah Medical Products has a net margin of 28.90% compared to Cooper Companies' net margin of 5.57%. Cooper Companies' return on equity of 10.88% beat Utah Medical Products' return on equity.

Company Net Margins Return on Equity Return on Assets
Cooper Companies5.57% 10.88% 7.27%
Utah Medical Products 28.90%9.13%8.86%

24.4% of Cooper Companies shares are owned by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are owned by institutional investors. 2.1% of Cooper Companies shares are owned by insiders. Comparatively, 8.0% of Utah Medical Products shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cooper Companies currently has a consensus target price of $81.31, suggesting a potential upside of 18.13%. Given Cooper Companies' stronger consensus rating and higher probable upside, equities analysts clearly believe Cooper Companies is more favorable than Utah Medical Products.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cooper Companies
3 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.38
Utah Medical Products
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Cooper Companies had 12 more articles in the media than Utah Medical Products. MarketBeat recorded 13 mentions for Cooper Companies and 1 mentions for Utah Medical Products. Cooper Companies' average media sentiment score of 0.56 beat Utah Medical Products' score of 0.00 indicating that Cooper Companies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cooper Companies
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Utah Medical Products
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cooper Companies has higher revenue and earnings than Utah Medical Products. Utah Medical Products is trading at a lower price-to-earnings ratio than Cooper Companies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cooper Companies$4.09B3.28$374.90M$1.1858.33
Utah Medical Products$38.52M5.49$11.29M$3.3819.67

Summary

Cooper Companies beats Utah Medical Products on 11 of the 17 factors compared between the two stocks.

Get Utah Medical Products News Delivered to You Automatically

Sign up to receive the latest news and ratings for UTMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UTMD vs. The Competition

MetricUtah Medical ProductsMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$207.63M$8.35B$6.74B$12.32B
Dividend Yield1.90%2.57%2.68%5.88%
P/E Ratio19.6715.2125.3923.96
Price / Sales5.497.01530.17107.90
Price / Cash14.6116.9345.2953.76
Price / Book1.793.2910.766.41
Net Income$11.29M$226.25M$3.56B$337.14M
7 Day Performance1.17%-0.96%1.37%-0.48%
1 Month Performance3.04%-2.77%0.81%0.49%
1 Year Performance19.29%0.16%30.53%28.16%

Utah Medical Products Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UTMD
Utah Medical Products
1.5082 of 5 stars
$66.47
+1.9%
N/A+18.8%$207.63M$38.52M19.67180
CERS
Cerus
3.0308 of 5 stars
$2.47
-2.0%
$4.00
+61.9%
+93.3%$504.93M$206.13MN/A290
OSUR
OraSure Technologies
1.3957 of 5 stars
$4.32
+3.6%
$3.00
-30.6%
+39.9%$287.10M$115.02MN/A840
ANIK
Anika Therapeutics
2.4819 of 5 stars
$14.30
-2.1%
$17.00
+18.9%
+33.6%$194.40M$112.82MN/A300
WST
West Pharmaceutical Services
3.3278 of 5 stars
$329.77
-0.5%
$340.09
+3.1%
+54.8%$23.41B$3.07B44.0910,800

Related Companies and Tools


This page (NASDAQ:UTMD) was last updated on 6/24/2026 by MarketBeat.com Staff.
From Our Partners